Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of Vunakizumab (SHR-1314) in adults with active psoriatic arthritis
CTR20243791Phase 3Active
- Sponsor
- Suzhou Shengdiya Biopharmaceuticals
- Start
- Nov 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of vunakizumab in psoriatic arthritis (PsA), sponsored by Suzhou Shengdiya Biopharmaceuticals. Started Nov 2024; status: active.
02
Drugs
vunakizumab
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on CTR20243791.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243791.